Boston Scientific has collaborated with Brainlab, a software-driven medical technology company.
Here are five key takeaways:
1. As part of the agreement, Boston Scientific will begin distributing the Brainlab Deep Brain Stimulation surgical planning portfolio with the Boston Scientific Vercise DBS System in select countries.
2. The collaboration provides patients and physicians with a comprehensive portfolio for deep brain stimulation therapy.
3. DBS therapy involves the placement of a device that stimulates specific areas of the brain using electrical signals. According to Maulik Nanavaty, president, Neuromodulation at Boston Scientific, "planning and visualization are important parts of the DBS process," which is what Brainlab's DBS surgical planning portfolio enables.
4. Brainlab supports treatments in radiosurgery as well as numerous surgical fields including neurosurgery, orthopedics and ENT.
5. Boston Scientific's Vercise DBS System has a CE Mark and is available in Europe, Israel, Australia and certain countries in Latin America and Asia Pacific. In the United States, it is investigational and not available for use or sale.